Key statistics
52-week range
Open | 1.42 |
---|---|
High | 1.43 |
Low | 1.34 |
Bid | 1.47 |
Offer | 1.55 |
Previous close | 1.47 |
Average volume | 0.00 |
---|---|
Shares outstanding | 90.66k |
Free float | 67.99k |
P/E (TTM) | -- |
Market cap | 3.63m USD |
EPS (TTM) | -224.68 USD |
Data delayed at least 15 minutes, as of Nov 12 2024.
More ▼
Announcements
- NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel
- NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States
- NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024
- NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study
- NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update
- NuCana to Present at the Jefferies Global Healthcare Conference
- NuCana to Present at TD Cowen’s 5th Annual Oncology Innovation Summit
- NuCana Reports First Quarter 2024 Financial Results and Provides Business Update
- NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement
- NuCana Announces Completion of ADS Ratio Change
More ▼